Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Vascular contributions

Topic: Brain proteins, microglia and lab models

White matter hyperintensity (WMH) is the core imaging hallmark of cerebral small vessel disease (CSVD). This phenomenon is closely related to nervous system damage, such as cognitive impairment, dementia and increased risk of stroke. However, traditional diagnostic methods have significant limitations in terms of quantitative assessment, analysis of pathological mechanisms, and clinical decision support, which severely restrict their clinical application. Through high-throughput feature extraction and comprehensive analysis of clinical, laboratory, histological, and genomic data, radiomics in its current form can not only achieve the high-precision identification and staging of WMH but also help to reveal its pathological mechanism, which has shown important value in the diagnosis, prognosis, and evaluation of WMH-related diseases. Against this backdrop, we strictly adhered to the norms of systematic literature reviews, conducting a comprehensive and transparent literature search. We also thoroughly reviewed the data using a predefined strategy and strict inclusion/exclusion criteria (detailed in the text). This article systematically reviews the progress of radiomics research in characterizing the pathological mechanism of WMH and in the early identification, classification and prognostic evaluation of related diseases, aiming to provide a theoretical basis and a technical reference for the early identification of high-risk groups, the optimization of diagnosis and treatment decision-making, and the practice of collaborative patient management.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Du, L., Wang, L., Shen, G., Zeng, M., Li, D., & Li, W. (2025). Progress of radiomics research on white matter hyperintensity lesions. Frontiers in Neurology. https://doi.org/10.3389/fneur.2025.1647724

Vancouver

Du L, Wang L, Shen G, Zeng M, Li D, Li W. Progress of radiomics research on white matter hyperintensity lesions. Frontiers in Neurology. 2025. doi:10.3389/fneur.2025.1647724. PMID: 40933048.

BibTeX

@article{du2025-40933048,
  author  = {Du, Lin and Wang, Lieping and Shen, Gang and Zeng, Min and Li, Desheng and Li, Weiguo},
  title   = {{Progress of radiomics research on white matter hyperintensity lesions}},
  journal = {Frontiers in Neurology},
  year    = {2025},
  doi     = {10.3389/fneur.2025.1647724},
  pmid    = {40933048},
  url     = {https://doi.org/10.3389/fneur.2025.1647724}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This review describes how radiomics, a method of extracting many features from imaging, may help identify and stage white matter hyperintensity lesions and reveal their pathological mechanisms. It is a review of research progress and does not report a treatment, cure, or prevention.

Study details

How this study scored 33/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomised / blinded 0 of 2; Times cited 1 of 7; Citations per year 0 of 5; Impact for its field and year 1 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 2 of 4; Institution's track record left out, no data; Multi-centre collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. 32 of the 97 points it could be judged on, which is 33 of 100. Total 33 of 100.32 of the 97 points we could judge = 33 of 100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on institution's track record, so that was left out: it earned 32 of the 97 points we could judge it on, which is 33 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Frontiers in Neurology)
Journal's citation record 2 / 4 Frontiers in Neurology: journal h-index 162 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 1 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.3 citations a year over 3 year(s) since 2025
Impact for its field and year 1 / 6 Cited 0.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Weiguo Li: h-index 21 (OpenAlex, whole career)
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multi-centre collaboration 0 / 3 OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40933048)
Free to read 2 / 2 Free to read
Points 32 / 97 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 32 of the 97 points we could judge it on is 33 out of 100.
Total 33 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Vascular contributions

Also tagged “vessel”

900 studies in the library carry the topic tag “vessel”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 900 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Vascular contributions

See all studies in Vascular contributions →